Login / Signup

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.

Carlo B Gambacorti-PasseriniFranck Emmanuel NicoliniRichard A LarsonAndrea AroldiDiletta FontanaRocco PiazzaPhilipp le CoutreLaura AntoliniSarit Assouline
Published in: American journal of hematology (2022)
Keyphrases
  • chronic myeloid leukemia
  • stem cells
  • mesenchymal stem cells
  • cell therapy
  • bone marrow
  • replacement therapy